Pre-eclampsia is a complex pathogenesis that requires a personalised medicine approach. The main goal of the IMPROvED project is therefore to develop a clinically robust predictive blood test for pre-eclampsia, using innovative technologies and utilizing novel metabolite and protein biomarkers. This blood test is targeted to all first time mothers during early pregnancy to determine their risk for this major pregnancy complication.
The IMPROvED project will develop a robust, sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia. It will demonstrate that development and application of new and improved technologies in the respective fields of metabolomics and proteomics can lead to truly novel screening tests. These tests can significantly reduce the burden of individual patients as well as burden to healthcare costs and society of a major healthcare problem: Pre-eclampsia.
Development of a predictive test and its application in a personalised medicine approach to stratify first time pregnant mothers would be a first and key step in the reduction and eventual prevention of the life-threatening complications of pre-eclampsia.